{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-095102","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.337820+00:00","generated_at":"2026-05-30T03:39:38.147853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rafael Holdings reports Q4 net loss $0.19/share; full year loss $1.45/share; merger with Cyclo ongoing","bullets":["Q4 net loss from continuing ops $4.5M ($0.19/diluted) vs gain $1.3M ($0.06) year ago.","Full year net loss $34.4M ($1.45/diluted) vs loss $8.4M ($0.36) prior year; includes $89.9M in-process R&D charge.","Cash and marketable securities $65.9M as of July 31, 2024.","Merger with Cyclo Therapeutics (CYTH) progressing; Phase 3 study fully enrolled, interim results mid-2025.","R&D expenses $4.2M for fiscal year, down from $6.3M due to winding down early-stage programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-095102","json":"https://secwatch.observer/filing/0001213900-24-095102.json","markdown":"https://secwatch.observer/filing/0001213900-24-095102.md","text":"https://secwatch.observer/filing/0001213900-24-095102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024095102/0001213900-24-095102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024095102/ea0218947-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:39:38.147853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}